Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,449 total articles
DDC Enterprise Limited announced a 29% year-over-year revenue increase to $20.2 million and positive non-GAAP Adjusted EBITDA of $1.2 million for the first half of 2026. The company improved working capital from negative $12.2 million to positive $39.4 million, grew total shareholders' equity substantially, and increased Bitcoin holdings by 145%. D…
Diginex Limited announced the departure of CEO Lubomila Jordanova and appointed interim CEO Archana Kotecha amid efforts to integrate recent acquisitions. The company also filed a listing application with Nasdaq seeking approval for a change of control related to the planned acquisition of Resulticks Global Companies Pte. Limited.
Madrigal Pharmaceuticals announced its participation in the 2026 Cantor Global Healthcare Conference where it will present its progress and pipeline advancements. The company specializes in treatments for metabolic dysfunction-associated steatohepatitis (MASH), highlighting its drug Rezdiffra, the first FDA and European Commission approved medicati…
DDC Enterprises Ltd. reported significant progress in the first half of 2026, showing a 29% revenue increase in its Asian food platform, positive adjusted EBITDA, and a large expansion of its Bitcoin treasury to 2,899 BTC. The company improved its working capital position substantially and launched a share repurchase program, while continuing to de…
Design Therapeutics, a clinical-stage biotech company developing GeneTAC® gene targeted chimera small molecule therapies for degenerative genetic diseases, announced management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference. The webcast will highlight the company's pipeline, including programs for Fri…
UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, announced it will participate in key healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global, and H.C. Wainwright events. Presentations will be webcast and available for replay on the company's website.
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company specializing in nitric oxide therapies, announced its management will participate in the 2026 Cantor Global Healthcare Conference. The company will hold a fireside chat and offer a webcast to discuss its latest developments, including its FDA-approved LungFit PH syste…
Aligos Therapeutics, a clinical-stage biotech company focused on liver and viral diseases, announced its management will present at the Cantor Global Healthcare Conference on September 9, 2026. The presentation will review the company's scientific approach and development of therapies, particularly for chronic hepatitis B. The company also highligh…
The U.S. Court of Appeals for the Second Circuit officially vacated a preliminary injunction that had restricted Genius Group Limited from issuing shares, raising capital, and purchasing Bitcoin. This marks the end of an 18-month legal battle with LZG International. The lifting of the injunction allows Genius Group to fully proceed with its board-a…
Milestone Pharmaceuticals Inc., a biopharmaceutical company specializing in cardiovascular medicines, announced that its management will present at several forthcoming investor conferences including Wells Fargo, Cantor Global Healthcare, and H.C. Wainwright. The company is known for its lead FDA-approved product CARDAMYST, a nasal spray treating pa…
vTv Therapeutics Inc., a late-stage biopharmaceutical company developing an oral investigational therapy for type 1 diabetes, will participate in two major investor conferences in September. The company’s leading drug candidate, cadisegliatin, a novel oral glucokinase activator with Breakthrough Therapy designation, is currently being evaluated in …
CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on bladder cancer immunotherapies, announced the participation of its CEO, Arthur Kuan, in the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in September 2026. The company will webcast the presentations live and make replays available to investors.
Insight Molecular Diagnostics Inc. announced its participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth Conference scheduled for September 10, 2026, where its CEO and CFO will engage in one-on-one investor meetings in New York City.
ProQR Therapeutics, a clinical-stage company specializing in RNA therapies, announced management's participation in Wells Fargo and Cantor Global Healthcare investor conferences in September 2026. The company will discuss its pioneering Axiomer™ RNA editing technology, which aims to develop new medicines by correcting RNA mutations. Webcasts will b…
Aemetis, Inc., a California-based renewable fuels company, praised the unanimous passage of California Senate Bill 795 which allows fuel retailers to dispense E15 ethanol fuel using existing vapor recovery equipment. The legislation resolves implementation delays and is expected to increase ethanol demand significantly, benefiting Aemetis' ethanol …
Alpha Tau Medical Ltd., a NASDAQ-listed Israeli oncology therapeutics company, announced that CFO Raphi Levy will participate in the Citi 2026 Biopharma Back to School Conference and H.C. Wainwright 28th Annual Global Investor Conference in September 2026 to engage with investors and discuss their innovative Alpha DaRT therapy for solid tumors.
Pasqal (Nasdaq: PSQL), a leader in neutral-atom quantum computing, and Saudi-based True Nexus have successfully used quantum technology to encode protein structures relevant to protein gelation. This collaboration represents a pivotal step toward understanding and designing protein functionality, a key challenge in the global food and biotech indus…
ALX Oncology Holdings Inc., a clinical-stage biotech company focused on cancer therapies, announced its leadership will present at three major investor conferences in September 2026. These events will include fireside chats and one-on-one meetings, during which the company will discuss its pipeline, including its lead candidate evorpacept and secon…
Acrivon Therapeutics, a clinical-stage biotech company using its proprietary Generative Phosphoproteomics AP3 platform, announced that its CEO will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference. The company is advancing innovative drug candidates including ACR-368 and ACR-2316, both showing promising clinical activi…
Eos Energy Enterprises, MN8 Energy, and Google have announced a collaborative project to deploy an 86 MW solar power plant integrated with 100 MWh zinc-based long-duration energy storage and 280 MWh lithium-ion storage in West Virginia. The project aims to provide clean, dispatchable power to the PJM grid to support Google's data centers and region…
Linkhome Holdings Inc. announced the formation of its wholly owned subsidiary, Linkhome Technologies Inc., focused on AI computing infrastructure and related services. The company has begun preliminary evaluation of a potential AI computing infrastructure project in Europe that could utilize up to 144 NVIDIA GB300 GPUs to support cloud, enterprise …
High Roller Technologies, Inc. announced the timing for the launch of its ROLR prediction markets platform, starting with an invitation-only beta on September 15, 2026, and targeting a full public commercial launch by October 2026. The beta phase aims to validate and optimize platform performance before broad market release, marking a significant m…
3 E Network Technology Group Limited announced a $1 million private placement of 701,272 Class A shares at approximately $1.426 each to a Singapore-based entity controlled by its CEO, Dr. Tingjun Yang. The funds will support general corporate purposes and working capital to accelerate growth and innovation. The transaction was approved by independe…
Polyrizon Ltd., a Nasdaq-listed biotech company, has completed contracting with all five U.S. clinical sites for its first-in-human trial of NASARIX™, an innovative intranasal hydrogel-based allergy blocker for seasonal allergic rhinitis. This progress marks the study's move into patient pre-screening and enrollment, targeting up to 120 participant…
Daktronics, Inc., a leader in digital display technologies, announced fiscal 2027 first quarter results with a 21.2% increase in diluted EPS to $0.40 on 7.1% sales growth, achieving a 10.6% operating margin. The company maintained a product backlog exceeding $300 million for the sixth straight quarter and ended the quarter with a strong cash positi…
